| Ytd | 24.04% | |
| 1y | 65.16% |
| Open | 34.84 | Prev Close | 34.84 | Low | 33.77 | High | 35.13 | Mkt Cap | 2.41B |
| Vol | 0.00 | Avg Vol | 425.73K | EPS | -3.19 | P/E | -10.80 | Forward P/E | -11.96 |
| Beta | -2.33 | Short Ratio | 2.09 | Inst. Own | 85.62% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 33.20 | 200-d Avg | 28.31 | 1yr Est | 48.39 |
PHVS News
ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma
Pharvaris is positioned to build a vertically integrated HAE franchise with deucrictibant in both im
The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical res
This late-stage biotech innovator in rare disease therapies reported significant insider selling ami
ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma
Does Pharvaris N.V. (PHVS) have what it takes to be a top stock pick for momentum investors?
Wells Fargo analyst Yanan Zhu initiates coverage on Pharvaris (NASDAQ:PHVS) with a Overweight rat
The mean of analysts' price targets for Pharvaris (PHVS) points to a 36.2% upside in the stock. Whil
ZUG, Switzerland, July 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma
ZUG, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma
ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmac
Pharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE
This clinical-stage biotech, focused on rare disease therapies, reported a notable insider sale amid
ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a lat
ZUG, Switzerland, May 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a lat
This biopharma innovator in rare disease therapies reported a notable insider sale amid a year of st
Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) CEO Berndt Modig sold 2,292 shares of the business's
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharm
This clinical-stage biotech focused on rare disease therapies reported a notable insider sale amid a
U.S. stocks traded down this morning, with the Nasdaq Composite falling more than 101 points on Frid